Synphatec (shanghai) Biopharmaceutical Technology Co., Ltd.

This Phase 1 trial is the first time SP-101 is being tested in humans. It will enroll 80 healthy adults to check the drug's safety, tolerability, and how the body processes it. SP-101 works by blocking NMDA receptors in the brain, a different approach from standard antidepressant…